A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little